OpenAI introduces GPT-Rosalind for life-sciences research; working with Amgen (AMGN), Moderna (MRNA), Thermo Fisher (TMO) and others

OpenAI's introduction of GPT-Rosalind marks a significant step in leveraging AI for life sciences research, collaborating with key industry players such as Amgen and Moderna.

Newsquawk StaffPublished On the live feed at 5 more headlines followed before this page went public
Newsquawk headlinesUTC

US oil companies warn US President Trump not to allow Iran to impose a toll on tankers transiting the Strait of Hormuz as part of a future peace deal, via FT

IAEA says Ukraine's Zaporizhzhia NPP temporarily lost all off-site power this evening; connection restored after about 40 minutes; cause of power loss not yet known

OpenAI introduces GPT-Rosalind for life-sciences research; working with Amgen (AMGN), Moderna (MRNA), Thermo Fisher (TMO) and others

Canada Trade Minister holds discussions with Chinese EV manufacturers, including BYD, Xpeng (XPEV), and Guangzhou Automobile Group;

CRUDE WRAP: WTI (M6) SETTLES USD 3.40 HIGHER AT USD 94.69/BBL; BRENT (M6) SETTLES USD 4.46 HIGHER AT USD 99.39/BBL

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.

Use Cases & Partnerships

  • Scientists can use new life sciences research plugin for Codex, available today in GitHub.
  • Working with customers like Amgen, Moderna, the Allen Institute, Thermo Fisher Scientific & others to apply GPT-Rosalind across workflows.
Context

This development could enhance R&D efficiencies in biotechnology and pharmaceuticals, but the broader implications for equity markets and investment appetite in these sectors may take time to unfold as analysts assess the tangible impact on productivity and innovation.

Related headlines

The whole workspace, free to try.

Try it free